Phase 2 Evidence and Impact Analysis
Article 1 — CRISPR-Cas9 CD33-deleted allogeneic HCT with GO maintenance in AML (PMID 42120728)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First-in-class application of CRISPR antigen deletion to protect a donor graft from post-transplant targeted therapy; platform concept is genuinely transformative |
| Clinical Relevance | 7 | Directly addresses post-HCT relapse in high-risk AML/MDS — a major unmet need — but trial stopped early (n=4 Phase 2), abstract only, 3 TRMs |
| Population Reach | 5 | |
| Implementation Speed | 2 | Gene-edited cell product requires regulatory approval, specialized manufacturing, Phase 2/3 trial completion; 7–10+ years realistic |
| Evidence Strength | 5 | Phase 1/2a, n=30, abstract only, early trial termination, 10% TRM; engraftment endpoint met but efficacy unproven |
Key quantitative result: 30/30 engraftment by Day 28 (median 10 days); GO maintenance tolerated up to 2 mg/m²; 3/30 TRM (10%); 19/30 received GO maintenance.
External validation: None; single-arm, no comparator.
Main limitation: Trial stopped early; Phase 2 expansion enrolled only n=4; no efficacy (OS/PFS) data; abstract only; 10% TRM is clinically significant.
Equity implications: Requires specialized academic HCT centers; likely inaccessible to patients in LMICs or underserved rural settings. Donor matching requirements add complexity for patients from underrepresented ethnic groups with limited donor registries.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 9 | Phase 2 composite: 5.7
Article 2 — Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN) (PMID 42120723)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First Phase 3 RCT establishing oral GLP-1RA as a step-down maintenance strategy after injectable; the concept is anticipated but the evidence is new and directly addresses a critical gap |
| Clinical Relevance | 9 | Directly solves a pressing clinical problem: most patients regain weight after stopping injectable GLP-1RAs; oral maintenance addresses cost, access, and tolerability barriers |
| Population Reach | 9 | Obesity affects >1 billion people globally; injectable GLP-1RA use is expanding rapidly; millions will need a maintenance strategy |
| Implementation Speed | 8 | Orforglipron is in regulatory review; Phase 3b data accelerates label expansion discussions; oral formulation removes cold-chain barriers; 1–3 years plausible |
| Evidence Strength | 8 | Phase 3b double-blind RCT, two cohorts, all secondary endpoints met, strong effect sizes (treatment differences 25.5–41.7%); industry-funded but robust design |
Key quantitative result: Orforglipron maintained 74.7% (post-tirzepatide) and 79.3% (post-semaglutide) of prior weight reduction vs 49.2% and 37.6% with placebo (both P<0.001); treatment differences of 25.5% and 41.7%.
External validation: Not independently replicated; single sponsor trial; companion to SURMOUNT-5 participants provides some continuity context.
Main limitation: Abstract only; 52-week data only; unclear long-term durability beyond the trial window; industry-funded (Eli Lilly); no head-to-head with continued injectable therapy.
Equity implications: Oral formulation is a major equity win — removes injection training burden, cold-chain requirements, and some cost barriers vs. injectables. However, cost of orforglipron itself will determine real-world access, particularly in LMICs and for uninsured patients. Does not yet include diverse populations with adequate reporting.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 9 | Phase 2 composite: 8.3
Article 3 — Unprocessed U1 snRNAs as a biomarker of INTS11- and BRAT1-related neurodevelopmental disorders (PMID 42116163)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First demonstration that BRAT1 mutations impair Integrator-mediated U1 snRNA processing; redefines BRAT1 disease as an Integrator disorder; opens new mechanistic pathway |
| Clinical Relevance | 7 | Directly enables variant reclassification for VUS-level BRAT1 diagnoses and introduces a quantitative severity biomarker; no treatment exists, but diagnostic clarity has immediate clinical utility |
| Population Reach | 4 | Ultra-rare disorders; absolute patient numbers are very small globally (~hundreds to low thousands known), but within this population unmet need is extreme and the biomarker is immediately applicable |
| Implementation Speed | 4 | Cell-based assay (fibroblasts/LCLs) requires clinical laboratory development and validation; could be implemented in specialized centers within 2–4 years; not yet widely available |
| Evidence Strength | 7 | Multi-institutional cohort + functional zebrafish validation + correlation of biomarker magnitude with clinical severity; Genome Medicine; patient cohort size unspecified but multi-site authorship; mixed species model appropriately caps ceiling |
Key quantitative result: U1 snRNA misprocessing magnitude correlates with clinical severity across BRAT1 patient cohort (quantitative correlation described; specific metrics not extractable from abstract).
External validation: Zebrafish knockout model independently recapitulates phenotype, providing orthogonal mechanistic validation.
Main limitation: Patient cohort size not reported in abstract; mixed-species model; abstract only; COI (zebrafish tools company co-founder among authors). Not therapeutic — biomarker only.
Equity implications: Rare disease diagnostics disproportionately help patients in high-resource settings who can access genomic testing. International authorship (UCL, Prague, Cairo, Bergen) is notable and may increase global accessibility of the assay. Families receiving VUS-level diagnoses — often in underserved diagnostic settings — are the primary beneficiaries.
Evidence Maturity: Validated ✓ (confirmed, with caveat: cohort size unspecified)
Triage score (OpenClaw): 9 | Phase 2 composite: 6.3
Article 4 — Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated GBM (PMID 42120910)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First DNA-based personalized vaccine encoding up to 40 neoantigens/patient in GBM; prior peptide vaccines exist but this multi-antigen DNA platform is a step change |
| Clinical Relevance | 6 | MGMT unmethylated GBM has median OS ~12–18 months with SOC; met pre-specified endpoints; 4-year survivor; but n=9 with no comparator arm |
| Population Reach | 4 | ~13,000 new GBM cases/year in US; MGMT unmethylated = ~60%, so ~7,800/year; extremely high unmet need within this group |
| Implementation Speed | 2 | Personalized manufacturing per patient, Phase 2 needed, regulatory pathway complex; 7–10 years minimum |
| Evidence Strength | 5 | Phase 1, n=9, single-arm, no comparator; Nature Cancer publication adds credibility but design inherently limited; abstract only |
Key quantitative result: 6-month PFS 66.7%; 12-month OS 66.7%; median PFS 8.5 months; median OS 16.3 months; 24-month survival 33%; 4-year survivor (1/9); T cell expansion in 8/9.
External validation: None; single-institution Phase 1.
Main limitation: n=9, no control arm, single-arm Phase 1, abstract only; survival endpoints not directly comparable to historical controls without adjustment; 1 patient excluded from immunogenicity analysis due to dexamethasone use.
Equity implications: Personalized manufacturing makes this prohibitively expensive for most patients globally. High-income academic center access only for foreseeable future. GBM affects all demographics; cost equity is the dominant barrier.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 8 | Phase 2 composite: 4.9
Article 5 — Pasteurized Akkermansia muciniphila MucT for weight loss maintenance (PMID 42120725)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First human RCT of pasteurized A. muciniphila as weight maintenance intervention; novel microbiome-pharmacology; mechanism distinct from all existing pharmacological approaches |
| Clinical Relevance | 7 | Addresses weight regain — the central challenge in obesity management — with a non-drug, orally administered, safe supplement; complements GLP-1RA landscape |
| Population Reach | 8 | Obesity affects >1 billion people; this intervention targets the weight maintenance phase after dietary weight loss, a near-universal challenge |
| Implementation Speed | 7 | Pasteurized supplement = no live organism regulatory hurdles; regulatory pathway faster than drug; 2–4 years plausible if larger trials confirm; already commercially available in some markets as supplement |
| Evidence Strength | 7 | RCT, n=90, pre-specified primary endpoint met, significant effect sizes, safe profile; 24-week maintenance window is relatively short; industry COI but design is sound |
Key quantitative result: 1.2±0.7 kg regain (MucT) vs 3.2±0.4 kg (placebo), P=0.012; net weight loss from baseline 3.1±0.7 kg MucT vs placebo (P=0.009).
External validation: Not independently replicated; first RCT of this specific formulation.
Main limitation: n=90, 24-week only, abstract only; industry COI (CTO of The Akkermansia Company among authors); no comparison with GLP-1RA step-down or other maintenance strategies.
Equity implications: Supplement formulation (if accessible) could be considerably cheaper than pharmaceutical GLP-1RAs. Baseline Akkermansia abundance as predictor of response may create biomarker-stratified access considerations. Global availability and affordability of clinical-grade pasteurized formulation unclear.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 8 | Phase 2 composite: 7.5
Article 6 — SPECTRAL photonic hydrogel platform for cancer prediction (PMID 42116274)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Highly novel integrated platform (photonic crystal hydrogel + PNA probes + ML) detecting 205 ctDNA mutations + 8 proteins simultaneously, sequencing-free |
| Clinical Relevance | 4 | Early feasibility; sample size undisclosed; three cancer types only; no head-to-head vs. approved liquid biopsy methods |
| Population Reach | 7 | Multi-cancer liquid biopsy applicable to lung, breast, colorectal cancer populations (hundreds of millions globally); democratization potential if validated |
| Implementation Speed | 2 | Preclinical feasibility stage; requires large prospective validation, regulatory approval, manufacturing scale-up; 8–12 years realistic |
| Evidence Strength | 3 | Classification confidence medium; sample size not disclosed; single-site feasibility study; no comparator; abstract only |
Key quantitative result: 90.0% specificity, 86.7% sensitivity, 87.5% overall accuracy across three cancer types.
External validation: None.
Main limitation: Sample size not disclosed; no comparator; single platform validation study; medium classification confidence.
Equity implications: Low-cost, sequencing-free platform design has strong equity potential for LMICs where sequencing infrastructure is limited — but validation and regulatory approval will favor high-income markets first.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 4.5
Article 7 — NUP98-rearranged AML mutational profiling and outcomes (PMID 42120929)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Largest adult NUP98r AML cohort; confirms and extends existing knowledge but not mechanistically novel |
| Clinical Relevance | 7 | Actionable: FLT3i use and HSCT independently improve survival; 53.3% 5-year OS with FLT3i is clinically meaningful in this adverse-risk group |
| Population Reach | 4 | NUP98r AML is ~3–5% of adult AML; small absolute numbers but high unmet need |
| Implementation Speed | 7 | FLT3 inhibitors are already approved; this study supports their use in NUP98r/FLT3-ITD patients; implementable with existing drugs |
| Evidence Strength | 6 | Retrospective multicenter cohort, n=95; largest adult series; no randomization; retrospective design limits causal inference |
Key quantitative result: Median OS 15.2 months overall; FLT3i-treated: median OS not reached, 5-year OS 53.3%; NUP98::NSD1 most common (54%).
External validation: Multicenter (French network) adds some validation; no independent external cohort.
Main limitation: Retrospective; no randomization; abstract only; no propensity adjustment described; historical treatment heterogeneity.
Equity implications: NUP98r AML disproportionately affects younger adults; access to FLT3 inhibitors varies by geography and insurance status. Patients in LMICs may lack access to these agents.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 5.8
Article 8 — BTKi vs VenR in second-line CLL: Czech real-world analysis (PMID 42120657)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Confirms similar efficacy already suggested by cross-trial comparisons; novel as first direct real-world comparison |
| Clinical Relevance | 7 | Directly informs treatment selection between two standard-of-care options; BTKi infection signal is actionable |
| Population Reach | 5 | CLL affects ~200,000 patients in US; second-line setting is a meaningful subset; globally relevant |
| Implementation Speed | 8 | Both agents are approved and in current use; findings immediately applicable to treatment selection counseling |
| Evidence Strength | 6 | Real-world retrospective cohort, n=352; largest direct comparison dataset; baseline imbalances not fully controlled; no propensity matching |
Key quantitative result: 12-month PFS 82.2% vs 85.1% (p=0.265); OS 88.4% vs 87.6% (p=0.291); BTKi discontinuation 34.3% vs 22.5% (infection-driven).
External validation: Single-country (Czech) data; not independently replicated.
Main limitation: Retrospective; baseline imbalances (higher TP53 mutation in BTKi group); no propensity matching; Czech healthcare context may limit generalizability.
Equity implications: Fixed-duration VenR may be preferable in lower-resource settings given finite treatment duration and potentially lower long-term cost. BTKi infection risk is disproportionate in immunocompromised and older patients.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 5.9
Article 9 — Single-cell mechanodeformation signatures in hematologic malignancies (review) (PMID 42118701)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Label-free biomechanical profiling is a genuinely novel diagnostic modality; review synthesizes emerging evidence |
| Clinical Relevance | 4 | No direct patient care change currently; clinical readiness not established; multi-site validation pending |
| Population Reach | 6 | Leukemias and myeloma affect hundreds of thousands; label-free approach could be additive to existing diagnostics |
| Implementation Speed | 2 | Technology not yet validated at multi-site scale; standardization and harmonization needed |
| Evidence Strength | 2 | Review article; no primary data; design quality inherently limited |
Main limitation: Review only; no original data; multi-site validation is the explicit gap.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.0
Article 10 — Immunopeptidomics with liquid biopsy for precision oncology (review) (PMID 42119346)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Integration of immunopeptidomics with liquid biopsy is a forward-looking conceptual advance; some methodological novelty |
| Clinical Relevance | 3 | Conceptual review only; no clinical data; years from patient impact |
| Population Reach | 6 | If realized, applicable to all solid tumor immunotherapy candidates |
| Implementation Speed | 1 | Very early conceptual stage; technical barriers are substantial |
| Evidence Strength | 2 | Narrative review; no primary data |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.5
Article 11 — ctDNA limited utility in pseudomyxoma peritonei (PMID 42119195)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Negative finding in a rare context; limited mechanistic novelty but clinically informative |
| Clinical Relevance | 6 | Important negative result: prevents misallocation of resources toward ctDNA monitoring in PMP; redirects surveillance strategy |
| Population Reach | 2 | PMP is very rare (~2–4 per million/year); limited absolute reach |
| Implementation Speed | 7 | Immediately actionable: informs against adopting ctDNA monitoring in PMP management |
| Evidence Strength | 6 | Prospective cohort, n=95, ddPCR methodology; reasonable design for this rare condition |
Key quantitative result: ctDNA detected in only 8/95 (8%) patients; median mutated allele frequency 0.1.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.7
Article 12 — Peripheral retinal haemorrhage density on UWF imaging for DR progression (PMID 42120190)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Peripheral UWF biomarkers are an emerging area; AI-quantification of haemorrhage density as specific predictor adds to existing knowledge |
| Clinical Relevance | 7 | Directly identifies high-risk patients for intensified surveillance; potentially changes DR screening protocols |
| Population Reach | 8 | ~537 million people with diabetes globally; DR is the leading cause of preventable blindness; peripheral imaging biomarkers applicable broadly |
| Implementation Speed | 7 | UWF imaging already in use at many eye centers; AI quantification tools are commercially available; near-term implementation feasible |
| Evidence Strength | 7 | Prospective 2-year longitudinal, n=528 eyes, multiethnic Asian cohort; independent OR calculations; robust design |
Key quantitative result: Peripheral haemorrhage density OR=3.09 (p=0.044); PPL OR=4.00 (p=0.040); 1.6× higher progression risk for PPLs.
External validation: Single-center (Singapore); multi-ethnic within cohort but not independently externally validated.
Main limitation: Single-center; Asian cohort only; 2-year window may miss later progressors; abstract only.
Equity implications: AI-UWF tools require upfront capital; may be unavailable in primary care diabetes clinics in LMICs. Singapore cohort may not generalize to all ethnic groups or healthcare systems.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 7.0
Article 13 — SHAP-interpretable ML model for stroke risk using serum miRNAs (PMID 42120650)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Interpretable ML + miRNA biomarkers is a familiar combination; SHAP application is incremental |
| Clinical Relevance | 4 | AUC 1.0 on training strongly suggests overfitting; external validation n=10 is insufficient |
| Population Reach | 7 | Stroke is the second leading cause of death globally; risk prediction tools have massive potential reach |
| Implementation Speed | 2 | Requires large prospective validation before any clinical use; external cohort of n=10 is not validation |
| Evidence Strength | 2 | Perfect training AUC = high overfitting probability; n=10 external validation is critically insufficient; medium classification confidence |
Main limitation: AUC 1.0 is a red flag for overfitting; external validation n=10 is scientifically inadequate for generalizability claims.
Evidence Maturity: Exploratory ✓ (confirmed; flagging concern about overfitting)
Triage score (OpenClaw): 6 | Phase 2 composite: 3.7
Article 14 — Single-cell impedance sensing chip for intraoperative tumor diagnosis (PMID 42120887)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | $1 semiconductor chip for 20-minute intraoperative differentiation is technically novel and cost-disruptive |
| Clinical Relevance | 5 | Intraoperative decision-making is a real clinical need; but sample size undisclosed, feasibility only |
| Population Reach | 7 | Applicable across 6 tumor types; intraoperative pathology is a universal surgical need |
| Implementation Speed | 3 | Requires clinical validation, regulatory approval, integration into surgical workflow; 5–8 years realistic |
| Evidence Strength | 3 | Feasibility study; sample size not disclosed; medium confidence; abstract only |
Main limitation: Sample size undisclosed; no sensitivity/specificity reported from abstract; single-institution feasibility.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.9
Article 15 — SERS + AI for CKD early diagnosis using serum KIM-1 (PMID 42120702)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SERS + XGBoost combination for KIM-1 is a technically novel biosensor approach |
| Clinical Relevance | 5 | CKD early detection is clinically important; but sample size and prospective validation absent |
| Population Reach | 8 | ~850 million people with CKD globally; early detection biomarkers have enormous potential reach |
| Implementation Speed | 3 | POC potential but requires prospective validation, regulatory approval |
| Evidence Strength | 2 | Sample size not disclosed; no prospective validation described; LOOCV only; medium confidence |
Main limitation: Sample size absent; no prospective cohort; 98.42% accuracy claims require external validation.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.5
Article 16 — MILA-MIL: Mamba-inspired linear attention for WSI survival prediction (PMID 42118628)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-branch Mamba-inspired architecture is architecturally novel within the MIL WSI space |
| Clinical Relevance | 4 | Computational pathology tool; no direct clinical validation; benchmark improvement over existing methods |
| Population Reach | 6 | Six diverse cancer cohorts; potentially applicable across oncology |
| Implementation Speed | 3 | Research-grade tool; requires clinical integration, prospective validation, EHR embedding |
| Evidence Strength | 5 | Multi-cohort computational validation; no prospective clinical outcome data; benchmark comparisons only |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.8
Article 17 — NSCLC blood proteomics: surgical and immunotherapeutic responses (PMID 42120924)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-platform (7596 + 250 proteins) multi-timepoint discovery with cross-platform validation is technically rigorous and incremental in novelty |
| Clinical Relevance | 5 | ICI response prediction and recurrence biomarkers are clinically relevant; but n=56, discovery-stage only |
| Population Reach | 7 | NSCLC is the most common cancer death globally; ICI response prediction has broad applicability |
| Implementation Speed | 3 | Biomarker discovery; requires prospective validation in larger cohorts before clinical use |
| Evidence Strength | 6 | Prospective multi-timepoint; dual-platform cross-validation; n=56 limits power; industry COI |
Key quantitative result: Lower baseline IL-6, CCL19, SPP1, PDCD1 in ICI responders; MUC16, IL36G, COX7A2L as recurrence signatures; validated by nELISA.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 5.3
Article 18 — CM-LP11 methylation biomarker for cutaneous melanoma prognosis (PMID 42118848)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Lactylation-related methylation as a prognostic model is a novel biological angle; relative methylation ordering approach is methodologically interesting |
| Clinical Relevance | 4 | Multi-cohort validation, but bioinformatics only; prospective clinical utility unproven |
| Population Reach | 5 | ~325,000 melanoma cases/year globally; TCGA training limits generalizability |
| Implementation Speed | 3 | Methylation profiling already available; but prospective validation and clinical integration needed |
| Evidence Strength | 5 | Three cohorts (n=699 total); retrospective; TCGA training set has well-known biases |
Evidence Maturity: Exploratory ✓ (confirmed; publication date placeholder noted)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.5
Article 19 — Feladilimab + docetaxel vs docetaxel in NSCLC (ENTRÉE Lung Sub-study 1) (PMID 42120929)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Negative ICOS agonist trial; confirms a hypothesis rather than disproving a known mechanism |
| Clinical Relevance | 7 | Negative RCT results have direct and immediate clinical relevance; closes off a development pathway |
| Population Reach | 6 | Advanced NSCLC post-checkpoint progression is a large, growing population globally |
| Implementation Speed | 8 | Negative result is immediately actionable — clinicians and sponsors can deprioritize this approach |
| Evidence Strength | 6 | Phase 2 RCT, n=105, randomized, platform design; open-label; underpowered for definitive conclusions |
Key quantitative result: OS HR 1.5 (95% CI 0.92–2.44); OS 7.8 vs 8.2 months; ORR 19% vs 11%.
Evidence Maturity: Validated ✓ (confirmed — negative finding is validated evidence)
Triage score (OpenClaw): 5 | Phase 2 composite: 5.9
Article 20 — FMISO PET changes as ICI response predictors in NSCLC (pilot) (PMID 42120578)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Hypoxia PET as dynamic ICI response monitor is novel; FMISO-PET in NSCLC ICI context is original |
| Clinical Relevance | 4 | n=17 pilot only; hypothesis-generating; insufficient for practice guidance |
| Population Reach | 6 | NSCLC ICI patients are a large population; PET response monitoring would be broadly applicable if validated |
| Implementation Speed | 2 | FMISO-PET is not routinely available; requires prospective trial before clinical use |
| Evidence Strength | 3 | n=17 pilot; no control arm; medium confidence; exploratory only |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.2
Article 21 — Alloantigen-expressing virotherapy for PDAC (preclinical) (PMID 42120181)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Exploiting MHC alloantigen mismatch rejection mechanisms to convert immune-cold PDAC is mechanistically creative and highly original |
| Clinical Relevance | 3 | Preclinical only; Clinical Relevance capped at 5 per non-human model rule; current data insufficient for clinical extrapolation |
| Population Reach | 5 | Pancreatic cancer kills ~50,000 in US/year; deeply unmet need; high reach relative to disease burden |
| Implementation Speed | 1 | Mouse model only; first-in-human trials likely 5–8+ years away |
| Evidence Strength | 4 | Two immunocompetent mouse PDAC models; rechallenge survival data; JITC publication; non-human cap applies |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.9
Article 22 — Healthcare costs of four obesity medications (real-world claims) (PMID 42120922)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | GLP-1RA cost burden is well-recognized; this study adds quantification with a large dataset but does not include newer weekly agents |
| Clinical Relevance | 6 | Directly relevant to formulary decisions and policy; liraglutide data is partially outdated but cost structure findings are informative |
| Population Reach | 9 | Obesity is a global epidemic; n=228,654 is a massive dataset; cost data affects coverage policies affecting millions |
| Implementation Speed | 7 | Findings immediately relevant to payers, policymakers, and prescribers |
| Evidence Strength | 6 | Very large retrospective claims study; includes only older agents (pre-semaglutide/tirzepatide); commercial claims only |
Key quantitative result: Liraglutide total costs 73.6% higher in year 1 vs phentermine; no favorable utilization changes to offset cost.
Main limitation: Pre-dates semaglutide and tirzepatide; commercial insurance only (excludes Medicaid/uninsured populations).
Evidence Maturity: Validated ✓ (confirmed, with caveat about drug vintage)
Triage score (OpenClaw): 6 | Phase 2 composite: 6.1
Article 23 — Prepregnancy GLP-1RA exposure and hypertensive disorders of pregnancy (PMID 42120704)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GLP-1RA prepregnancy safety in obese/diabetic women is a clinically urgent and understudied area |
| Clinical Relevance | 6 | Safety signal for preeclampsia in a growing real-world exposure scenario; but n=31 exposed is critically small |
| Population Reach | 7 | Millions of reproductive-age women are now prescribed GLP-1RAs; safety data during pregnancy is a major knowledge gap |
| Implementation Speed | 5 | Signal warrants clinical attention but cannot change guidelines without larger data; immediate utility is awareness-raising |
| Evidence Strength | 2 | n=31 exposed; retrospective EHR; propensity-matched but underpowered; medium confidence |
Main limitation: n=31 exposed — severely underpowered; observational; confounding by indication likely.
Evidence Maturity: Exploratory ✓ (confirmed; hypothesis-generating only)
Triage score (OpenClaw): 5 | Phase 2 composite: 5.3
Article 24 — Caring role and cognitive function trajectory in later life (ELSA) (PMID 42120013)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Caring role as bidirectional cognitive modifier is a novel angle; large longitudinal study adds empirical weight |
| Clinical Relevance | 5 | Relevant to carer support policy and geriatric medicine; no direct treatment implication |
| Population Reach | 7 | ~53 million informal carers in the US; aging globally; this affects a massive population |
| Implementation Speed | 6 | Policy and carer support interventions are addressable without new technology; findings translatable to public health guidance |
| Evidence Strength | 7 | ELSA longitudinal (19 years, n=5530 matched), propensity-matching, robust design |
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 5.9
Article 25 — Gut microbiota remodeling during aging (review) (PMID 42118429)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Reviews well-established aging-microbiome literature; primarily a synthesis |
| Clinical Relevance | 3 | Review only; no new clinical data |
| Population Reach | 7 | Universal aging population relevance |
| Implementation Speed | 2 | Conceptual review; no near-term clinical translation |
| Evidence Strength | 2 | Narrative review; no primary data |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.6